Aljian Capital Management’s Gilead Sciences GILD Stock Holding History

Aljian Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$568K	Sell	4,496 -18	-0.4%	-$2.37K	0.11%	86
2026 Q1	$629K	Buy	4,514 +13	+0.3%	+$1.82K	0.13%	78
2025 Q4	$552K	Sell	4,501 -385	-8%	-$46.8K	0.11%	79
2025 Q3	$542K	Buy	4,886 +17	+0.3%	+$1.93K	0.11%	83
2025 Q2	$540K	Sell	4,869 -873	-15%	-$92.9K	0.12%	80
2025 Q1	$643K	Sell	5,742 -1	-0%	-$103	0.15%	76
2024 Q4	$530K	Buy	5,743 +28	+0.5%	+$2.52K	0.12%	76
2024 Q3	$479K	Buy	+5,715	New	+$436K	0.11%	79

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aljian Capital Management's GILD Position: Q2 2026 in Review

Aljian Capital Management reduced its Gilead Sciences (GILD) stake by 0.4% in Q2 2026, selling an estimated $2.37K and leaving 4,496 shares worth $568K. The position accounts for 0.11% of the portfolio, ranked #86.

Aljian Capital Management first reported a position in GILD in Q3 2024 and has held it in 8 quarters since. The position peaked at $643K in Q1 2025. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Aljian Capital Management held 4,496 shares of Gilead Sciences worth $568K as of Q2 2026.
Aljian Capital Management sold 18 Gilead Sciences shares in Q2 2026, an estimated $2.37K.
Gilead Sciences made up 0.11% of Aljian Capital Management's portfolio in Q2 2026, its #86 holding.
Aljian Capital Management first reported a position in Gilead Sciences in Q3 2024 and has held it in 8 quarters since.
Aljian Capital Management's Gilead Sciences position peaked at $643K in Q1 2025.
2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Aljian Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.